And there seems to be a glimmer of hope in the NXCEL1311 study (81), whose interim results indicated that the combination of EGFR antibody and dCRT significantly improved the 3-month CRR and objective response rate in patients with LA-ESCC compared with dCRT alone. The gene discussed is EGFR; the disease is esophageal squamous cell carcinoma.